ClinicalTrials.gg
CompletedNCT01250834Updated Oct 8, 2014Results posted

LY2189265 and Atorvastatin Interaction Study

A Phase 1 interventional study of Atorvastatin and LY2189265 in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-08.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will assess if giving LY2189265 at the same time as atorvastatin affects how the body absorbs atorvastatin.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects with female partners of : Agree and whose partners agree to use two reliable methods of from the time of the first dose until 3 months after the last dose of study drug, as determined by the investigator.
  • Female subjects not of child-bearing potential (that is, are or permanently sterilized [for example, tubal occlusion, hysterectomy, bilateral salpingectomy]) will not be required to use contraception. Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) with follicle stimulating hormone (FSH) greater than or equal to 40 milliInternational Units per milliliter (mIU/mL).
  • Female subjects who have undergone sterilization by tubal ligation: Agree to use a male or female condom used in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of study drug. Such subjects must also test negative for pregnancy at the time of enrollment.
  • Have a (BMI) between 18.5 and 30.0 kilograms per square meter (kg/m\^2), inclusive.
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not by the investigator.
  • Have venous access sufficient to allow frequent blood sampling.
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow the study restrictions

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, or discontinued within the last 90 days from a clinical trial involving an drug or device or off-label use of a drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have known allergies or intolerance to atorvastatin.
  • Have known allergies to glucagon-like peptide-1 (GLP-1)-related compounds including LY2189265.
  • Are persons who have previously completed or withdrawn from this study, or have taken part in any other study investigating LY2189265 or GLP-1-related compounds or incretin mimetics within the last 3 months.
  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have an abnormal blood pressure (after at least 5 minutes sitting) that, in the opinion of the investigator, increases the risks associated with participating in the study.
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, for example esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts absorption and distribution of study drugs (for example, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs.
  • Have a history or presence of thyroid disease.
  • Show history or evidence of significant active neuropsychiatric disease.
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
  • Show evidence of (HIV) and/or positive human HIV antibodies.
  • Show evidence of and/or positive hepatitis C antibody.
  • Show evidence of and/or positive hepatitis B surface antigen.
  • Intend to use over-the-counter medication within 7 days prior to dosing or prescription medication (with the exception of vitamin/mineral supplements and/or hormone replacement therapy) within 14 days prior to dosing.
  • Use drugs that are known substrates, inducers, or inhibitors of cytochrome P450 (CYP) enzyme pathways or phosphorylated glycoprotein (P-gp) within 14 days prior to the first dose.
  • Have donated blood of more than 500 mL within the month prior to screening.
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), and are subjects unwilling to stop alcohol consumption from 48 hours before Admission (Day -1) until discharge from the unit for each treatment period, and to limit alcohol intake to a maximum of 2 units/day on all other days from screening through 48 hours prior to the post-study visit (1 unit = 12 ounces (oz) or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
  • Are subjects who, in the opinion of the investigator, are in any way unsuitable to participate in the study.
  • Are women of child bearing potential
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    LY2189265 + Atorvastatin

    Period 1: Participants received a single 40-milligram (mg) oral dose of atorvastatin on Day 1, followed by a 7- to 10-day washout period between Period 1 and Period 2. Period 2: Participants received a single 1.5-mg subcutaneous dose of LY2189265 on Day 1, followed by a single 40-mg oral dose of atorvastatin on Day 3.

    Drug: Atorvastatin · Biological: LY2189265

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of Atorvastatin: Maximum Plasma Concentration (Cmax)

    Time frame: Pre-dose to 56 hours post-dose

  2. Pharmacokinetics of Atorvastatin: Area Under the Curve (AUC)

    This measure is based on the pharmacokinetic area under the atorvastatin plasma concentration-time curve from time 0 to infinity.

    Time frame: Pre-dose to 56 hours post-dose

Secondary outcomes

  1. Pharmacokinetics of Para-Hydroxyatorvastatin: Maximum Concentration (Cmax)

    Time frame: Pre-dose to 56 hours post-dose

  2. Pharmacokinetics of Para-Hydroxyatorvastatin: Area Under the Curve (AUC)

    This measure is based on the pharmacokinetic area under the para-hydroxyatorvastatin concentration-time curve from time 0 to infinity. The outcome is not available for this metabolite since the terminal elimination phase was not determinable.

    Time frame: Pre-dose to 56 hours post-dose

  3. Pharmacokinetics of Ortho-Hydroxyatorvastatin: Maximum Concentration (Cmax)

    Time frame: Pre-dose to 56 hours post-dose

  4. Pharmacokinetics of Ortho-Hydroxyatorvastatin: Area Under the Curve (AUC)

    This measure is based on the pharmacokinetic area under the ortho-hydroxyatorvastatin concentration-time curve from time 0 to infinity.

    Time frame: Pre-dose to 56 hours post-dose

07

Results

Posted Oct 8, 2014

Participant flow

Participant flow — Overall Study
MilestoneLY2189265 + Atorvastatin
Started27
Completed27
Not completed0

Outcome measures

PrimaryPharmacokinetics of Atorvastatin: Maximum Plasma Concentration (Cmax)
Time frame:
Pre-dose to 56 hours post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics of Atorvastatin: Maximum Plasma Concentration (Cmax)
nanogram per milliliter (ng/mL)40 mg Atorvastatin Alone1.5 mg LY2189265 + 40 mg Atorvastatin
Pharmacokinetics of Atorvastatin: Maximum Plasma Concentration (Cmax)19.5 ± 605.78 ± 86
PrimaryPharmacokinetics of Atorvastatin: Area Under the Curve (AUC)

This measure is based on the pharmacokinetic area under the atorvastatin plasma concentration-time curve from time 0 to infinity.

Time frame:
Pre-dose to 56 hours post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics of Atorvastatin: Area Under the Curve (AUC)
nanogram*hour per milliliter (ng*h/mL)40 mg Atorvastatin Alone1.5 mg LY2189265 + 40 mg Atorvastatin
Pharmacokinetics of Atorvastatin: Area Under the Curve (AUC)82.8 ± 3365.9 ± 35
SecondaryPharmacokinetics of Para-Hydroxyatorvastatin: Maximum Concentration (Cmax)
Time frame:
Pre-dose to 56 hours post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics of Para-Hydroxyatorvastatin: Maximum Concentration (Cmax)
nanogram per milliliter (ng/mL)40 mg Atorvastatin Alone1.5 mg LY2189265 + 40 mg Atorvastatin
Pharmacokinetics of Para-Hydroxyatorvastatin: Maximum Concentration (Cmax)0.473 ± 810.360 ± 69
SecondaryPharmacokinetics of Para-Hydroxyatorvastatin: Area Under the Curve (AUC)

This measure is based on the pharmacokinetic area under the para-hydroxyatorvastatin concentration-time curve from time 0 to infinity. The outcome is not available for this metabolite since the terminal elimination phase was not determinable.

Time frame:
Pre-dose to 56 hours post-dose

No measurements were reported for this outcome.

SecondaryPharmacokinetics of Ortho-Hydroxyatorvastatin: Maximum Concentration (Cmax)
Time frame:
Pre-dose to 56 hours post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics of Ortho-Hydroxyatorvastatin: Maximum Concentration (Cmax)
nanogram per milliliter (ng/mL)40 mg Atorvastatin Alone1.5 mg LY2189265 + 40 mg Atorvastatin
Pharmacokinetics of Ortho-Hydroxyatorvastatin: Maximum Concentration (Cmax)14.4 ± 465.66 ± 60
SecondaryPharmacokinetics of Ortho-Hydroxyatorvastatin: Area Under the Curve (AUC)

This measure is based on the pharmacokinetic area under the ortho-hydroxyatorvastatin concentration-time curve from time 0 to infinity.

Time frame:
Pre-dose to 56 hours post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics of Ortho-Hydroxyatorvastatin: Area Under the Curve (AUC)
nanogram*hour per milliliter (ng*h/mL)40 mg Atorvastatin Alone1.5 mg LY2189265 + 40 mg Atorvastatin
Pharmacokinetics of Ortho-Hydroxyatorvastatin: Area Under the Curve (AUC)102 ± 3095.9 ± 28

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
40 mg Atorvastatin Alone—0/27 (0%)8/27 (29.6%)
1.5 mg LY2189265—0/27 (0%)23/27 (85.2%)
1.5 mg LY2189265 + 40 mg Atorvastatin—0/27 (0%)16/27 (59.3%)
Most frequent other events
Showing 10 of 39
Most frequent other events
Event40 mg Atorvastatin Alone1.5 mg LY21892651.5 mg LY2189265 + 40 mg Atorvastatin
Decreased appetiteMetabolism and nutrition disorders0/2712/273/27
Abdominal distensionGastrointestinal disorders0/279/271/27
NauseaGastrointestinal disorders0/279/273/27
VomitingGastrointestinal disorders0/274/274/27
Abdominal painGastrointestinal disorders0/270/273/27
DyspepsiaGastrointestinal disorders0/271/273/27
HeadacheNervous system disorders0/273/271/27
LethargyNervous system disorders0/273/270/27
Abdominal discomfortGastrointestinal disorders0/272/270/27
DiarrhoeaGastrointestinal disorders1/270/272/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)LY2189265 + Atorvastatin
Mean42.7 ± 15.1
Sex: Female, Male
Sex: Female, Male(Participants)LY2189265 + Atorvastatin
Female12
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY2189265 + Atorvastatin
Hispanic or Latino0
Not Hispanic or Latino27
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY2189265 + Atorvastatin
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White25
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)LY2189265 + Atorvastatin
United Kingdom27
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leeds, West Yorkshire LS2 9LH, United Kingdom
09

References and documents

Publications

  • de la Pena A, Cui X, Geiser J, Loghin C. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Clin Pharmacokinet. 2017 Nov;56(11):1415-1427. doi: 10.1007/s40262-017-0531-7. PubMed 28357715 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2010
First posted
Dec 1, 2010
Start
Dec 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Oct 8, 2014
Last update
Oct 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01250834
Responsible party
Sponsor
First posted
Dec 1, 2010
Start date
Dec 2010
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Oct 8, 2014
Last update
Oct 8, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Dulaglutide

Start the discussion